Factors influencing effectiveness of deferiprone in a thalassaemia major clinical setting

Acta Haematologica

Volumn 104, Issue 2-3, 2000, Pages 99-102

  Del Vecchio, Giovanni Carlo ^a   Crollo, Elisabetta ^a   Schettini, Federico ^a   Schettini, Francesco ^a   Fischer, Roland ^b   De Mattia, Domenico ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Deferiprone; Oral chelator; Thalassaemia

Indexed keywords

DEFERIPRONE; IRON;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; IRON CHELATION; IRON OVERLOAD; ITALY; LIVER LEVEL; MALE; PRIORITY JOURNAL; SCHOOL CHILD; THALASSEMIA MAJOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CHILD; FEMALE; FERRITINS; HUMANS; IRON; IRON CHELATING AGENTS; LIVER; MAGNETICS; MALE; PREDICTIVE VALUE OF TESTS; PYRIDONES;

EID: 0034517557     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000039759     Document Type: Article

References (23)

1. Meta-analytic review of the clinical effectiveness of oral deferiprone (L-1)
2. An investigation into variability in the therapeutic response to deferiprone in patients with thalassemia major
3. Magnetic-susceptibility measurement of human iron stores
4. Liver iron quantification in the diagnosis and therapy control of iron overload patients
5. Biomagnetic susceptometer with SQUID instrumentation
6. Development of iron chelator L1
7. Toxicity of oral iron chelator L1
8. Evaluation of new iron chelators for clinical use
9. Reduction of tissue iron stores and normalisation of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia
10. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major
11. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial
12. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypirid-4-one (L1) in iron-loaded patients with sickle cell disease
13. Iron-chelation therapy with oral deferiprone in patients with thalassemia major
14. Liver iron stores in patients with secondary haemosiderosis under iron chelation therapy with deferoxamine or deferiprone
15. Combined therapy with deferiprone and desferrioxamine
16. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major
17. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients
18. Oral iron chelating therpy. A single centre interim report on deferiprone (L1) in thalassemia
19. Methods for evaluating iron stores and efficacy of chelation in transfusional hemosiderosis
20. Iron-chelating therapy and the treatment of thalassemia
21. Survival of medically treated patients with homozygous β-thalassemia
22. Assessment of iron stores in children with transfusion siderosis by biomagnetic liver susceptometry